Search Bar & Filters
Found 102 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are conducting an observational study to understand the short-term progression of geographic atrophy GA caused by age-related macular degeneration AMD in adults aged 55 and older. The goal is to identify participants with progressive GA and measure structural and functional changes, while exploring possible links to genetic and lifestyle factors. Participants will not receive any investigational treatments during this non-interventional study. Instead, their condition will be closely monitored over time using imaging techniques such as fundus autofluorescence FAF and optical coherence tomography OCT. The study will include assessments at baseline, month 3, and month 6 to track GA progression and related changes. Throughout the study, participants will undergo various eye examinations including visual acuity tests and microperimetry to measure retinal sensitivity. Researchers will collect data on GA progression and analyze correlations with genetic and lifestyle aspects. The study aims to provide detailed insight into GA changes over six months, with safety and adherence monitored by the research team. Participation will last approximately six months with scheduled visits for assessments.
Actively Recruiting
Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.
Actively Recruiting
Researchers are evaluating the use of methylprednisolone before surgery in patients undergoing major liver surgery called hepatectomy. The main goal is to see if methylprednisolone can reduce side effects of surgery, such as infections and longer hospital stays. This is a randomized controlled trial comparing methylprednisolone with the standard care without steroids.
Actively Recruiting
Healthy Volunteer
This study evaluates the immediate and long-term effects of structured breathing exercises on mental health symptoms such as anxiety, depression, perceived stress, and sleep quality in healthcare professionals. The research aims to understand how breathing practices might support mental well-being and resilience in this population. Participants will engage in self-guided structured breathing sessions lasting 15, 30, or 36 minutes, tailored to their personal skill level. These sessions are designed to improve brain circulation and mental well-being. The study uses a single group design without a comparison group, focusing on this breathing intervention over a four-month period. Throughout the study, participants will use a mobile app to track adherence, engagement, and satisfaction with the breathing exercises. Researchers will assess feasibility through recruitment ease, retention rates, and intervention acceptability. Mental health outcomes and participant feedback will be collected at regular intervals during the four months of study participation.
Actively Recruiting
Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.
Actively Recruiting
Researchers are studying adults aged 18 and older with warm autoimmune hemolytic anemia wAIHA, a condition where the immune system destroys red blood cells. This Phase 3 trial evaluates the effects, safety, and how the body processes rilzabrutinib compared with a placebo. The goal is to see if rilzabrutinib can increase hemoglobin levels sustainably in participants who have had the disease for at least six months and have not responded well to corticosteroid treatments. Participants will be randomly assigned in a 21 ratio to receive either oral rilzabrutinib or a placebo twice daily during the primary analysis period lasting up to 24 weeks. Those who complete this period can enter an open-label phase lasting 28 weeks where all receive rilzabrutinib. Participants who show improved hemoglobin levels near the end of this phase may continue in a long-term extension that lasts up to 52 weeks from the start of the extension. The study includes a safety follow-up of two weeks after treatment completion or discontinuation. Throughout the study, participants will have multiple visits for assessments including blood tests to measure hemoglobin changes, fatigue levels, and lung function, among others. Researchers will monitor for side effects, vital signs, and laboratory values up to 104 weeks. The primary outcome is the proportion of participants achieving a durable hemoglobin response between weeks 12 and 24. Secondary outcomes include overall hemoglobin response, fatigue improvement, and safety events. The total study duration for participants may extend up to several years depending on eligibility for the long-term extension.
1-10 of 102
1